Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec, a biotechnology group engaged in the discovery and development of small molecule drugs, has announced that Joern Aldag will resign from his position as its president and CEO, effective as of December 31, 2008.
Subscribe to our email newsletter
According to the company, Mario Polywka, COO, and Klaus Maleck, CFO, will jointly lead the organization until a permanent successor is announced.
Flemming Ornskov, chairman of the supervisory board of Evotec, said: “During his 11-year tenure at Evotec, Joern Aldag played a pivotal role in the transformation of Evotec from a technology provider to an integrated, CNS-focused biopharmaceutical company. Today the company has a very strong financial position and a deep preclinical and clinical pipeline of CNS drug candidates that provide a strong basis for future success.
“On behalf of the Evotec supervisory board, I would like to thank Joern Aldag for his effective and very successful leadership of the company and we wish him ongoing success for his future endeavors.”